Summary:
Syst-Eur is a multicenter placebo-controlled outcome trial designed by the European Working Pany on High Blood Pressure in the Elderly to investigate the effect of antihypertensive treatment on the incidence of stroke in elderly patients with isolated systolic hypertension (ISH). Eligible patients must be at least 60 years old and have a systolic blood pressure averaging 160-919 mm Hg with a diastolic blood pressure <95 mm Hg. The present paper is an interim report on the first 316 patients randomized into this trial. The placebo (n = 170) and active treatment (n = 146) groups were similar at randomization with respect to age (73 = . This first interim report on the Syst-Eur trial demonstrates that a multinational trial in elderly patients with ISH is feasible and that a significant blood pressure difference between the two treatment groups can be achieved and maintained. New centers are being recruited in order to randomize a total of 3.000 patients. Key Words: Clinical trial-Elderly-Isolated systolic hypenension-Pilot study.
Several major intervention trials on the treatment (I)]. T h e results in elderly patients with combined of hypertension have been published during the last , systolic a n d diastolic hypertension demonstrate t w o decades. Most of these trials have recruited that antihypertensive treatment o n average reduces young and middle-aged patients with combined syscardiovascu1ar mortality b y 28%, mainly through a tolic and diastolic hypertension, but some trials also decrease in t h e incidence of stroke ( -41%) ( I ) .
included patients 60 years o r older [for review see
In most countries systolic blood pressure contin-
I21
ues to rise beyond the age of 50 years, while diastolic blood pressure decreases in the elderly, leading to a widening of the pulse pressure (2-4 subjects randomized into this study.
METHODS
The protocol of the Syst-Eur trial has been published in detail elsewhere (23,) . The entry criteria for the patients include: (a) age of at least 60 years and (b) sitting blood pressure of 160-219 mm Hg systolic with a diastolic pressure <95 mm Hg on placebo during a run-in period. After a single-blind run-in period on placebo and after stratification by center, sex. and the presence or absence of cardiovascular complications, the patients are randomized to double-blind treatment with either active drugs or matching placebos. The following conditions lead to stratification into the subgroups with cardiovascular complications: myocardial infarction > I year prior to randomization; previous episodes of congestive heart failure; a history of thromboemboiic stroke without lasting sequelae: a previous transient ischemic attack and the presence of left ventricular hypertrophy or nondissecting aneurysm (22) .
Active treatment consists of nitrendipine (1040 mgl day) combined with enalapril (5-20 mglday) and hydrochlorothiazide (12.5-25 mglday), as necessary. The patients of the control group receive matching placebos. The active drugs (or matching placebos) are titrated in a stepwise manner and combined in order to reach the goal pressure. The latter is defined as a sitting systolic blood pressure < 150 mm Hg with a reduction in the sitting systolic blood pressure following randomization by at least 20 mm Hg.
Data base management and statistical analyses were performed using SAS software (23). The average differences between the blood pressure at randomization and the last available measurement within the first 9 months following randomization were compared for the active treatment and placebo groups (24) . Means were compared using Student's t test, and the proportion of patients reaching goal pressure were compared with the chisquare statistic. Mortality, morbidity, and adverse events are being monitored, but this paper deals only with the effects of randomized treatment on blood pressure.
RESULTS

Characteristics of the patients on admission
On March 1. 1991, 517 patients from 1 1 countries had been entered into the placebo run-in period of the trial. Of these 316 had been randomized; 160 patients who did not comply with the entry criteria had been removed from follow-up, and 41 patients were still progressing through the run-in period.
The characteristics of the 316 patients randomized into the double-blind trial are given in Table 1 .
Age averaged 73 5 8 years (mean 2 SD) and ranged from 60 to 96 years. Only 34% of the randomized patients were men. and 29% showed cardiovascular complications at entry.
Follow-up
The maximum follow-up varied because the patients had been entered over a period of several months. A total of !52 patients had been followed for at least 3 months. A follow-up of 9 months was attained in 82 patients.
Blood pressure during double-blind treatment
In the placebo group the fall in sitting systolic blood pressure over the initial 6 months following randomization averaged 5 2 18 mm Hg, and the change in the sitting diastolic blood pressure averaged 0 ? 9 mm Hg (Fig. 1) . In the patients assigned active treatment. the sitting systolic blood pressure (Fig. 1 ) . The changes in the standing blood pressure during the initial 6 months of placebo treatment averaged -4 + 17 mm Hg systolic and 1 t 9 mm Hg diastolic. At 6 months on active treatment the standing blood pressure had fallen by 14 2 21 mm Hg systolic and 6 2 I2 mm Hg diastolic. At the 6-month visit 11% of the patients assigned to the placebo group showed a fall in their standing systolic blood pressure by 2 2 0 mm Hg. This was the case in 12% of the patients omactive treatment.
The fall in blood pressure from randomization to the last available measurement within the first 9 months following randomization was greater on active treatment than on placebo: A total of 152 patients were examined at least on one occasion following randomization. Of these. 12% in the placebo and 31% in the active.treatment group had attained the target blood pressure. The percentage of patients reaching the target blood pressure during double-blind follow-up was signifi- cantly greater with active treatment than placebo (Fig. 2) .
Treatment administered during the double-blind period
The number of study drugs (placebo or active) taken by the patients at the 9-month visit is given in Table 2 , according to achievement of the. target blood pressure. In the patients randomized to active treatment and taking a specific drug, the daily dose of nitrendipine at the 9-month visit averaged 34 2 I 1 rng (n = 28), the dose of enalapril averaged 13 2 7 mg (n = 18), and the dose of hydrochlorothiazide 
DISCUSSION
The EWPHE decided to undertake the Syst-Eur trial (22) be prevented by medical treatment. I n 1985 EWPHE had already concluded a clinical trial on the antihypertensive treatment of elderly patients with combined systolic and diastolic hypertension (19) (20) (21) . The expertise and structures ensuing from this previous trial (19) (20) (21) were very helpful for organizing Syst-Eur because they provided the framework within which the new trial was conceived.
Two trials in elderly hypertensive patients. published before 1989. included a subgroup of ISH patients (9.25) but failed to demonstrate a significant treatment effect on outcome events. possibly because of the small number of patients with ISH (9.25) . Besides the present study (22), at least two other double-blind placebo-controlled trials are addressing the hypothesis that antihypertensive treatment is beneficial. specifically in elderly patients with ISH. namely the SHEP (12) (13) (14) (15) (16) (17) (18) 
in the United
States, and a trial in China (Lisheng Liu. personal communication).
The mortality and morbidity results of the SHEP trial consist of a significant reduction of nonfatal stroke (37%). nonfatal myocardial infarction (33%). and left ventricular failure (54%) in the active treatment group compared with placebo. whereas the decrease in transient ischemic attacks was not significant (18). Total mortality and mortality from cerebrovascular and coronary causes were also not significantly changed by active treatment (18). In contrast to the previous intervention studies in elderly patients with both systolic and diastolic hypertension (19-21.25) . fatal stroke and total cardiovascular mortality did not significantly decrease on active treatment in SHEP (18). However, when nonfatal-and fatal-outcome events in the SHEP trial were combined. the 5-year cumulative incidence rate of total stroke was reduced by 36% (p = n o of patients 0.0003). Adverse reactions were more often observed in the active treatment than in the placebo group with, for instance. significant increases in faintness on standing, falls. loss of consciousness, memory troubles, sexual dysfunction. change in bowel habits, and ankle swelling (18). None of the subjective complaints reported in the SHEP publication was more frequently noticed in the-placebo group (18).
In SHEP 447.921 subjects were screened to enroll up to 4.736 participants (18). A conservative estimate based on published prevalence figures for ISH in the elderly (5) is that a population with a similar age distribution and size as those screened for SHEP would probably include close to 60,000 cases. Thus. the subjects randomized into the SHEP trial are a selected subgroup, and may not be entirely representative of the majority of patients with ISH in the population at large.
After publication of the SHEP results. Syst-Eur's ethics and with the European Community liaison committees decided that it was ethical to continue the Syst-Eur trial. but that full consultation of all In the present study, the patients were followed for up to 9 months. The sitting blood pressure fell on average 1315 mm Hg more on active treatment than on placebo. In the S H E P pilot study (17) . after 1 year of treatment the differences between the two treatment groups were 17 mm Hg systolic and 6 mm Hg diastolic. However, in the fifth year of followup, when 44% of the S H E P patients assigned to the placebo group were actually receiving drugs with known antihypertensive action, the difference was 12 mm Hg systolic and 4 mm Hg diastolic (18). In most controlled trials on the efficacy of antihypertensive drugs in elderly patients with predominant systolic hypertension diuretics were the firstline medication (9.12.2630). The reduction in systolic blood pressure in the actively treated patients as compared with the control group averaged 12 mm Hg; the 95% confidence interval for the mean reduction in systolic blood pressure ranged from 5 to 20 mm Hg ( 5 ) . The mean effect in these studies (9.12.26-30) on diastolic pressure was a reduction of 3 mm Hg. with a 95% confidence interval ranging from 0 to 6 mm Hg.
The goal pressure in the present study was defined as a sitting systolic blood pressure <I50 mm Hg, with a reduction following randomization by at least 20 mm Hg (22). The target pressure is to be achievedby. the stepwise titration and combination of nitrendipine, enalapril, and hydrochlorothiazide o r matching placebos in the control group. Three months after randomization, the target systolic blood pressure was reached in 7% of the patients randomized to placebo arid 14% of the patients on active treatment: after 6 months these figures were 7 and 3396, respectively. It was indeed planned that the target blood pressure would be reached progressively over several months in order to avoid side effects in these elderly patients or an excessive, sudden fall in blood pressure, possibly leading to orthostatic hypotension. As follow-up is extended, randomized treatment will be further adjusted so that an even larger proportion of the patients on active treatment will achieve the target blood pressure.
In conclusion, this first interim report on the Syst-Eur trial demonstrates that a significant difference in systolic blood pressure between the two treatment arms can be achieved and maintaine New centers are now being recruited in order randomize a total of 3,000 patients.
